Aquestive Therapeutics, Inc. AQST
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
Aquestive Therapeutics, Inc. (AQST) is a healthcare company listed in the US with a market value of about $491M. In the twelve months to September 30, 2026 it had revenue of $49M and net income of -$79M, a net margin of -162.3%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -1% a year, a 5-year average ROIC of -436%.
About Aquestive Therapeutics
Aquestive Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. Revenue went from $67M in 2017 to $45M in 2025, a decline of about 5.0% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 119% over three years (dilution for shareholders). It spends 39% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $49M | $45M | $58M | $51M | $48M | $51M | $46M | $53M | $67M | $67M |
| Net income | -$79M | -$84M | -$44M | -$8M | -$54M | -$71M | -$56M | -$66M | -$61M | -$9M |
| Free cash flow | -$41M | -$53M | -$36M | -$7M | -$11M | -$34M | -$46M | -$61M | -$15M | $4M |
| EPS (diluted) | $-0.65 | $-0.78 | $-0.51 | $-0.13 | $-1.12 | $-1.85 | $-1.66 | $-2.61 | $-2.96 | — |
| Net margin | -162.3% | -188.1% | -76.7% | -15.6% | -114.1% | -138.8% | -121.7% | -125.9% | -91.0% | -13.4% |
| ROIC | — | -435.7% | — | — | — | — | -652.2% | -82.5% | -333.3% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $9.33, 139% above the current price; targets range from $6.00 to $11.00; the consensus rating is “Strong buy”; expected EPS is $-0.40 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Aquestive Therapeutics pay a dividend?
Not currently.
Is Aquestive Therapeutics a good stock to buy?
We do not give buy or sell advice. Aquestive Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.